Collaborations

Orion has entered into numerous collaborations and license agreements with leading corporations and academic institutions world-wide. Our collaborations have allowed Orion to strengthen our proprietary biomarker discovery and validation platform and our product pipeline. A summary of each collaborative or commercial agreement is shown here:

Collaboration and Commercial Agreements
 
Institution Description of Collaboration
Novartis Molecular Diagnostics Use Orion's proprietary DNA methylation technologies to discover novel epigenetic biomarkers and to commercialize diagnostic products under a multi-year collaboration and license agreement in multiple fields and a grant to Novartis of a non-exclusive world-wide license to MethylScreen clinical assay technology.
Malaysian Palm Oil Board Develop genomics tools for oil palm research, and to leverage MethylScope and MethylScreen technologies to discover biomarkers for somaclonal variation.
Johns Hopkins University School of Medicine Baltimore, MD Co-develop sensitive and specific molecular assay to detect the loss of Imprinting of IGF2 in patient samples.
Mayo Clinic Rochester, MN Study the clinical utility of Orion's proprietary biomarkers in more than a dozen cancer types.
University of Glasgow Scotland, UK Use MethylScope and MethylScreen technologies to identify biomarkers useful in the detection and treatment of lung, breast, and ovarian cancer.
Washington University School of Medicine Employ MethylScope and MethylScreen technologies in several collaborations with leading researchers to discover novel biomarkers for the development of tests that screen for cancer at an early stage and provide information about how tumors should be treated.
Johns Hopkins University School of Medicine Baltimore, MD Identify biomarkers correlating with colon cancer and psychiatric disorder using Orion's MethylScope technology.
ViaLactia Biosciences (NZ) Limited Leverage Orion's proprietary DNA methylation technologies to study the genome the perennial rye grass and clover genomes.